July 4, 2022
Not intended for U.S. and UK Media – New late-breaking data from Phase III ARASENS trial presented in the Game Changer oral session at the European Association of Urology Congress 2022 (EAU22)
Darolutamide plus androgen deprivation therapy and docetaxel demonstrates consistent overall survival benefits across various patient segments in metastatic hormone-sensitive prostate cancer
